Strengthening primary eye care in South Africa: An assessment of services and prospective evaluation of a health systems support package

PloS One
Rivka R LilianRemco P H Peters

Abstract

Visual impairment is a significant public health concern, particularly in low- and middle-income countries where eye care is predominantly provided at the primary healthcare (PHC) level, known as primary eye care. This study aimed to perform an evaluation of primary eye care services in three districts of South Africa and to assess whether an ophthalmic health system strengthening (HSS) package could improve these services. Baseline surveys were conducted in Cape Winelands District, Johannesburg Health District and Mopani District at 14, 25 and 36 PHC facilities, respectively. Thereafter, the HSS package, comprising group training, individual mentoring, stakeholder engagement and resource provision, was implemented in 20 intervention sites in Mopani District, with the remaining 16 Mopani facilities serving as control sites. At baseline, less than half the facilities in Johannesburg and Mopani had dedicated eye care personnel or sufficient space to measure visual acuity. Although visual acuity charts were available in most facilities, <50% assessed patients at the correct distance. Median score for availability of nine essential drugs was <70%. Referral criteria knowledge was highest in Cape Winelands and Johannesburg, with poor...Continue Reading

References

Oct 1, 1993·International Ophthalmology·M F al Faran, B I Ibechukwu
Jan 5, 2001·Curationis·M de Wet, L Ackermann
Dec 6, 2001·The British Journal of Ophthalmology·R Dandona, L Dandona
Jan 24, 2002·Reproductive Health Matters
Aug 27, 2003·Investigative Ophthalmology & Visual Science·Kovin S NaidooLeon B Ellwein
Jun 20, 2007·The British Journal of Ophthalmology·Colin CookHans Limburg
Oct 26, 2007·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Kovin Naidoo
Sep 23, 2009·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·John Bongaarts
Sep 8, 2010·Annals of Tropical Medicine and Parasitology·P CourtrightS Lewallen
Dec 3, 2011·The British Journal of Ophthalmology·Donatella Pascolini, Silvio Paolo Mariotti
Mar 20, 2013·BMC Health Services Research·Rènée du ToitPaul Courtright
May 16, 2013·PloS One·Ellen E FreemanMaria Victoria Zunzunegui
Nov 10, 2013·BMJ Open·Juliane KöberleinRobert P Finger
Jun 17, 2014·Primary Care Diabetes·Elizabeth M WebbDanie G Van Zyl
Aug 12, 2014·The Lancet Global Health·Robert J Casson
Apr 11, 2015·Human Resources for Health·Khumbo KaluaPaul Courtright
Sep 24, 2015·Ophthalmic Epidemiology·Jacqueline RamkeClare E Gilbert
Mar 18, 2016·Human Resources for Health·Paul CourtrightSusan Lewallen
Sep 2, 2016·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Hlupheka Lawrence Sithole
May 20, 2017·Epidemiology and Infection·E SchaftenaarR P H Peters
Oct 17, 2017·The Lancet Global Health·Seth R FlaxmanUNKNOWN Vision Loss Expert Group of the Global Burden of Disease Study

❮ Previous
Next ❯

Citations

Jan 21, 2020·Indian Journal of Ophthalmology·Maria Vittoria CicinelliRohit C Khanna
Aug 19, 2020·BMC Health Services Research·Kwadwo Owusu AkuffoPriscilla Reddy

❮ Previous
Next ❯

Software Mentioned

Stata
epsem
Excel
Epi Info TM

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.